Off-label use in Palliative Care – more common than expected. A retrospective chart review

Author:

Hagemann Vera,Bausewein Claudia,Rémi ConstanzeORCID

Abstract

AbstractObjectiveOff-label drug use seems to be integral to palliative care pharmacotherapy. Balancing potential risks and benefits in the context of limited therapeutic options is challenging. To provide specific support for clinicians in dealing with off-label use, it is essential to understand off-label use in everyday clinical practice.The aim of this pilot study was to quantify and describe off-label use in a palliative care unit.MethodsRetrospective chart review of all adult patients treated on a palliative care unit in 10/2017. All data on drug use e.g. indication, dose, route of administration were extracted and matched with the prescribing information. Identified off-label use was subsequently compared with recommendations in the relevant literature. The main outcome measure was frequency and type of off-label drug use.Results2,352 drug application days (d) and 93 drugs were identified for 28 patients. Of all drugs, 47 (51%) were used off-label at least once. Most off-label uses concerned indication (57%), followed by mode of administration. In drugs highly relevant to palliative care the rate of off-label use was as high as 67%. The extent to which off-label therapy was supported by literature was very variable and ranged from 0 to 88%.ConclusionsThis single-unit data confirms the high prevalence of off-label use in palliative medicine and demonstrates that off-label use in palliative care is very multifaceted. The data presented allows for a more precise characterization of various aspects of off-label use in order to derive concrete further measures for research and clinical practice.What is already known on this subjectOff-label drug use is likely to be common in palliative care, but detailed data is very limitedOff-label drug use is a potential threat for patient safetyPhysicians state to make therapeutic decisions based on their own experience, due to a lack of available evidence and lack of support in assessmentWhat this study addsoff-label use in palliative care is multifacetedthe mode of administration (e.g. combination with other drugs in a syringe driver) is beside indication a common reasons for off label usethe proportion of off-label use without sound evidence is high.

Publisher

Cold Spring Harbor Laboratory

Reference24 articles.

1. Drug use beyond the licence in palliative care: A systematic review and narrative synthesis;Palliative Medicine,2019

2. Unlicensed uses for medication in a palliative care unit

3. Use of unlicensed medication in palliative medicine;Palliative Medicine,1999

4. García-López I , Cuervas-Mons Vendrell M , Martín Romero I , de Noriega I , Benedí González J , Martino-Alba R. Off-Label and Unlicensed Drugs in Pediatric Palliative Care: A Prospective Observational Study. Journal of pain and symptom management. 2020.

5. FDA. Understanding Unapproved Use of Approved Drugs “Off Label” [cited 2019 Feb 05]. 2018 [updated 02/05/201808/02/2019]. Available from: https://www.fda.gov/forpatients/other/offlabel/default.htm.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3